Molecularly-matched therapy (MMT) is associated with increased response rates and in some cases with improved survival. Next generation sequencing (NGS) - based multigene panels offer a wide range of analyzed markers. There is a need to optimize comprehensive profiling and find the most relevant molecular targets according to tumor type.